Back

Targeting fibrosis: pirfenidone and beyond.

27 May 2019 (16:52 - 17:15)
Organised by:
Congress Presentation Part of: Upcoming and novel drugs in heart failure Drugs, Drug Targets HFA Premium Access Heart Failure 2019

About the speaker

Photo
Professor Rudolf De Boer

Erasmus University Medical Centre, Rotterdam (Netherlands (The))

3 More presentations in this session

Presentation thumbnail
Targeting cardiac amyloidosis.
Professor S. Heymans (Maastricht, NL)
Slides Video
Presentation thumbnail
Elamipretide, to block mitochondrial dysfunction?
Professor C. Maack (Wuerzburg, DE)
Slides
Presentation thumbnail
Gene therapy.
Professor Y. Pinto (Amsterdam, NL)

Access the full session

Session thumbnail
Upcoming and novel drugs in heart failure

The Event

Event poster

Heart Failure 2019

27 May 2019 16:52 CET
You may be interested in
thumbnail
Congress Presentation
Pirfenidone added to standard therapy for myocardial infarction further reduces left ventricular fibrosis: a preclinical study
21 May 2022
thumbnail
Congress Session
Does aldosterone synthase inhibition hold a key to transforming cardiorenal care?
19 May 2025
thumbnail
Congress Presentation
The interaction of bone morphogenetic protein receptor type 2 and pentraxin 3 on inflammation and fibrosis: implications for pulmonary hypertension
29 August 2025
thumbnail
Congress Presentation
Circulating pro fibrotic protein promotes fibrosis in liver and heart
1 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources